Editas Medicine Receives Australian Clinical Approval for Gene Editing Therapy and Wells Fargo Upgrades Rating
WFC Wells Fargo & Co
$82.03 +2.21%
View chart & analysis → 
- 1Editas Medicine has received approval from Australian authorities to begin the Phase 1/2 Strive trial of EDIT-401.
- 2Wells Fargo upgraded its rating on EDIT from 'Equal Weight' to 'Overweight' and set an increased price target of $6.
- 3Editas Medicine held $211.6 million in cash and cash equivalents as of June 30.
So what's the key point?
Editas Medicine is now able to start testing its gene editing therapy in Australia. Wells Fargo expects the stock to rise and has raised its target price to $6.
Source Stocktwits +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.